Kazia Therapeutics Launches Groundbreaking Clinical Trial Combining Paxalisib and Immunotherapy for Advanced Breast Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch...

January 31, 2025 | Friday | News
CPC Launches MicroCNX® Nano Series Aseptic Connectors to Transform Cell and Gene Therapy Processing

CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical pro...

January 30, 2025 | Thursday | News
Datar Cancer Genetics Launches AI-Powered Video Reporting Service for Chemosensitivity Testing

Datar Cancer Genetics (DCG) has launched a revolutionary video reporting service for in vitro chemosensitivity testing, powered by AI-based technology. Thi...

January 29, 2025 | Wednesday | News
European Commission Approves LAZCLUZE® (lazertinib) and RYBREVANT® (amivantamab) for First-Line Treatment of EGFR-Mutant Advanced NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...

January 28, 2025 | Tuesday | News
Merck’s WELIREG® (belzutifan) Accepted for Priority Review by FDA for Advanced Pheochromocytoma and Paraganglioma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for prior...

January 28, 2025 | Tuesday | News
Roche Reports Positive Two-Year Results from EMBARK Trial for Elevidys™, First Gene Therapy for Duchenne Muscular Dystrophy

Roche announced  positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (de...

January 28, 2025 | Tuesday | News
Tevogen Bio Expands AI Partnership with Microsoft to Accelerate Immunotherapy Development

Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d...

January 27, 2025 | Monday | News
Biogen’s LEQEMBI® Gains FDA Approval for Once Every Four Weeks Maintenance Dosing in Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

January 27, 2025 | Monday | News
Merck and Eisai Announce Promising Interim Results from LEAP-015 Trial of KEYTRUDA® and LENVIMA® in HER2-Negative Gastroesophageal Adenocarcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...

January 27, 2025 | Monday | News
GC Cell Hosts First Thought Leadership Symposium in Jakarta, Showcasing Immuncell-LC’s Potential in Cancer Treatment

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 23, 2025 | Thursday | News
Gilead Receives FDA Approval for Yescarta® Label Update, Showing Significant Overall Survival Benefit in Second-Line Treatment for Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axica...

January 23, 2025 | Thursday | News
Silexion Therapeutics Reveals Synergistic Efficacy of SIL-204 in Combination with Chemotherapy for Pancreatic Cancer

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...

January 17, 2025 | Friday | News
Bio-Rad Launches Nuvia wPrime 2A Media for Scalable Biomolecule Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced the launch of ...

January 15, 2025 | Wednesday | News
Libtayo® Demonstrates Significant Improvement in Disease-Free Survival for High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 C-POST Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment wi...

January 14, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close